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ABSTRACT
Myelomeningocele (MMC) constitutes the most common congenital defect of the central nervous system, with no satisfac-
tory alternative to the postnatal treatment. Prenatal repair of MMC is aimed at protecting from a Chiari type II malforma-
tion. The main goal of fetal MMC repair is to improve the development and quality of life in children with a Chiari type 
II malformation. The Management of Myelomeningocele Study (MOMS), which was published in 2011, confirmed the 
effectiveness of prenatal surgery. In this paper, we compared the MOMS results with our own clinical experience. Owing 
to high effectiveness and significant improvement in the safety of the maternal-fetal surgery, prenatal MMC repair has 
become a new standard of treatment.
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INTRODUCTION
Fetal myelomeningocele (fMMC) is one of the most 
common neural tube defects (NTDs). The results of the 
current postnatal treatment are not satisfactory. Owing to 
significant advances in ultrasound diagnostic imaging and 
primary perinatal care, fMMC may be identified as early 
as 16–18 weeks of gestation. Early detection of different 
types of NTDs enables to arrange the delivery, followed by 
postnatal surgical treatment, in a tertiary referral center. 
However, only prenatal surgical treatment, known as the in 
utero MMC repair (IUMR), protects the fetus from developing 
a Chiari II malformation (CM II).
Fetal MMC, a serious congenital neural tube defect, is 
also the most common defect of the central nervous sys- 
tem [1]. The incidence of MMC in the USA has been estima- 
ted at 2/10 000 live births, whereas in Poland MMC affects 
approximately 6/10 000 live births [2, 3].
The risk factors for the development of fMMC include 
antispasmodic, antihistamine and sulfonamide drug use 
in pregnancy, maternal diabetes and obesity, as well as 
familial NTD. Insufficient folic acid supplementation and 
the presence of the 677C > T polymorphism in the methyl-
enetetrahydrofolate reductase gene are the key factors for 
developing NTD [4]. 
POSTNATAL MMC REPAIR AND FOLLOW-UP 
IN CHILDREN WITH CM II
Since the 1960s, postnatal MMC surgery technique 
of tensing the surrounding layers of fascia, muscles and 
skin with Limberg’s modification has remained the pri-
mary treatment option, performed in the first 48 hours 
of life. Figure 1 shows newborns after delivery scheduled 
for postnatal MMC repair. In utero evolution of CM II en-
tails serious neural defects, which are generally caused 
by hydrocephaly (HC) and hindbrain herniation (HH) [5]. 
As a consequence of spinal cord exposure to the amniotic 
fluid, motor function of the lower extremities is lost, and 
bladder and bowel dysfunction are observed [6]. Clinical 
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implications depend on the level of spina bifida and spinal 
cord impairment. Defects lower down of the spinal cord are 
associated with better prognosis. A defect in cerebrospinal 
fluid circulation, which is caused by the displacement of the 
hindbrain structures into the spinal canal, results in HC in 
80–90% of the children with fMMC. About 80% of patients 
with fMMC require postnatal treatment such as endoscopic 
third ventriculostomy (ETV) or insertion of the ventriculo-
peritoneal shunt (VPS), which allows excess CSF to drain 
to the peritoneal cavity [7]. VPS placement is associated 
with numerous complications concerning its obstruction 
or infection [8]. Early Polish results of postnatal treatment 
show high rate (85%) of progressive HC when temporary 
Rickham reservoir placement, followed by VPS insertion, 
was necessary [9]. 
The prognosis for children with MMC is grave. Despite 
intensive treatment, almost 14% of all children with MMC 
die during the first 5 years of life, and the mortality rate 
increases up to 35% when cerebellar dysfunction (second-
ary to CM II) develops [10]. About 70% of children reach 
the IQ level > 80, but only approximately half of them are 
self-reliant in adulthood [11].
THE REASONS FOR PRENATAL FMMC 
SURGERY AND EARLY CLINICAL EXPERIENCES
In 1990, Heffez et al., introduced the ‘two-hit’ theory, 
demonstrating a connection between neurological defects 
in children with MMC and the effect of two hits: neurulation 
in the early embryo life occurs, and then myelodysplasia 
is exaggerated in the mechanism of inflammation — the 
first hit (activated by the components of the amniotic fluid) 
— and mechanical destruction of spinal cord hitting the 
womb — the second hit [12].
Pathological and morphological studies on the spinal 
cord of fetuses (early and late pregnancy) and newborns 
with MMC reported progression of plaque defragmenta-
tion, spinal cord injury and nerve fiber destruction. These 
changes escalated with the duration of pregnancy [13].
The next experimental studies concerning IUMR in 
a sheep model disclosed that the loss of neurological func-
tion is then arrested. Especially, it became possible to main-
tain the motor function of the lower extremities, sustain 
normal cortex width and vegetative functions [14].
Finally, an experimental study of IUMR in human fetus 
showed reversibility and even regression of HC and HH, 
which are typical for CM II [15].
First IUMRs were reported in 1997–1998 at the Vanderbilt 
University Medical Center and at the Children’s Hospital of 
Philadelphia (CHOP) [16, 17]. Their early reports confirmed the 
theoretical and experimental assumption that in utero protec-
tion of the nerve fibers suppresses CM II evolution, resulting 
in HH reduction, stationary HC and maintaining motor func-
tion of the lower extremities [18, 19]. In the follow-up study, 
the VPS implantation rate was lower in the IUMR group as 
compared to the group treated postnatally (90% vs. 46%). The 
observed motor function of the lower extremities reflected 
motor functions typical for the injury of two spinal segments 
below the actual anatomical MMC level [19].
THE MOMS RANDOMIZED STUDY RESULTS
In 2011, the MOMS randomized study proved beyond any 
doubt the efficacy of prenatal surgery [20]. After enrollment 
and randomization of 183 out of the 200 recruited patients, 
the benefits of the prenatal surgery were confirmed and the 
study was completed. The rate of VPS placement in 1-year-old 
children who had undergone IUMR was significantly lower as 
compared to the postnatally treated patients (40% vs. 80%; 
relative risk, 0.8; 97.7% CI, 0.36–0.64; p < 0.001). Motor func-
tion of the legs (at 30 months of follow-up) was also better in 
the prenatally treated children: 42% of the prenatally and 21% 
of the postnatally treated children (relative risk 2.01; 95% CI, 
1.16–3.48; p = 0.01) could walk independently. Among chil-
dren in the IUMR group, the rate of patients without HH was 
decreased as compared to the postnatally treated group (36% 
vs. 4%; relative risk 0.67; 95% CI, 0.56–0.81, p < 0.001). Vegeta-
tive dysfunctions, especially concerning bladder, are the most 
burdensome problems in MMC patients. Unfortunately, so far 
it has not been proven that surgical treatment in utero could 
favorably influence the functioning of the urinary system [21].
The MOMS study pointed out that iatrogenic complica-
tions, which arise from the invasiveness of the procedure, 
belong to the main IUMR limitations. IUMR increases the risk 
of iatrogenic preterm premature rupture of the membranes 
(iPPROM) (46% vs. 4% ; relative risk 6.15; 95% CI, 2.75–13.78; 
p < 0.001), oligohydramnios (21% vs. 4%; relative risk 5.47; 
95% CI, 16–18.4; p < 0.001) and inflammation-induced pre-
term labor (iPTL) (79% vs. 15%). As a result, higher incidence 
of children with low birth weight and respiratory distress 
syndrome is observed [20].
A five-year study of preschool children with MMC treated 
prenatally revealed that psychomotor development corre-
sponded to their age in 83% of the cases. A 10-year observa-
tional study showed that behavioral functions were normal 
Figure 1. fMMC of three newborns delivered at 36–37 weeks for 
a scheduled operation after birth
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in most patients and improvement of motor functions of 
legs was maintained in 90% of the affected children [23].
FMMC REPAIR — POLISH CLINICAL EXPERIENCE
In Poland, the first successful in utero fMMC repair was 
performed by Preis in 2004 [24]. Since 2005, 74 prenatal 
surgeries have been conducted at the Clinical Department 
of Gynecology, Obstetrics and Oncological Gynecology of 
the Silesian Medical University in Bytom, in cooperation 
with the pediatric surgeons from the Clinical Department 
of Pediatric Surgery in Katowice. In our first report on pre-
natal MMC closure in 10 patients, no increase in the lateral 
ventricular width was observed postoperatively [25]. Fig-
ure 2 demonstrates basic stages of IUMR. Since the surgery 
up to the delivery, the value remained within the qualifica-
tion criterion of < 18 mm. In the next report, concerning 
31 IUMR cases, control fetal MRI revealed that 13 out of 
19 fetuses demonstrated HH reduction and no progression 
was noticed in 6 cases [26]. In our non-randomized study, 
we compared a group of 46 fetuses treated in utero to 47 pa-
tients with MMC postnatal closure [28]. In this observation 
up to 53 months of life, decreased VPS implantation rate 
the first group (27.8% vs. 80%; CI 0.35, 0.16–0.75; p < 0.008), 
lower HH (11% vs. 70%; CI 0.16, 0.04–0.06, p < 0.01), and 
better motor function were noticed in the first group. As 
in the MOMS study, we demonstrated that prenatal sur-
gery is associated with the risk of iPTL, iPPROM and uterine 
wound dehiscence. As a consequence of iPPROM and iPTL, 
advanced neonatal procedures are required. After IUMR 
surgery, the cumulative mortality among newborns < 7 days 
of life reached 4.3% (2 newborns). In our last study of 71 fe-
tuses with fMMC treated in utero, reduced HH and station-
ary HC were observed in 96.9% and 53.2% of the patients 
(36 cases), respectively. Only 15 newborns (21.1%) presented 
progressive HC (AD > 95 pct.). 29.5% of the pregnancies were 
delivered before 30 weeks of gestation and 18.3% (13 cases) 
reached 37 weeks of gestation. Cumulative mortality was 
4.2% (2 newborns), and was comparable to the MOMS result 
of 3% (2 out of 78 cases) and to the recently published study 
of VUMC — 5% (3 out of 43 cases) [30]. 
A NEW STANDARD — FETAL MMC CLOSURE. 
POST-MOMS ERA
The main goal of prenatal MMC closure is to improve 
psychomotor development and the quality of life in pa-
tients with Chiari malformation. The latest studies, known 
as ‘post-MOMS era’ and published after 2011, showed high 
safety of the maternal-fetal surgery [13]. Bennet et al. com-
pared the results of a cohort study of 43 pregnancies after 
IUMR with the results of the randomized MOMS study re-
sults, and demonstrated that improved technical skills in the 
IUMR procedure lowered the rate of iPPROM (22% vs. 46%, 
p = 0.011) and chorioamniotic separation (0% vs. 26%, 
p < 0.001). Mean time of pregnancy after IUMR in the cohort 
study was extended up to 34.4 ± 6.6 vs. 34.1 ± 3.1 weeks of 
gestation. Also, the number of preterm births < 30 weeks 
was reduced to 2 (4%) vs. 10 (13%) (p = 0.08). 
Satisfactory results of perinatal care in patients who 
underwent IUMR depend not only on the fetal-surgery team, 
but also on their understanding of the need to cooperate 
and achieve common goals [31]. Figure 3 presents an MMC 
site after prenatal surgery. The presented results have dem-
onstrated high efficacy of IUMR. The studies from the last 
three decades have been finally accepted by the interna-
Figure 2. IUMR stages (A — hysterotomy; B — stabilization of the fetus with exposed MMC, 
a — uterus, b — fetal back, c — MMC sack; C — closed MMC; D — closed uterus) 
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tional societies of obstetricians and gynecologists (ACOG, 
SOGC) for selected inclusion and exclusion criteria (Table 1) 
[32–34]. The Polish Gynecological Society published their 
recommendations about eligibility and the IUMR surgical 
procedure in 2006 [35].
EDUCATION OF THE PARENTS AND THE 
APPROACH AFTER MMC DIAGNOSIS
In cases when a NTD such as non-lethal fMMC is diag-
nosed, the parents should be informed about three possible 
treatment options:
 Ū postnatal treatment performed within 24 hours of life,
 Ū prenatal fMMC closure for patients who meet the 
eligibility criteria,
 Ū pregnancy termination.
Medical consultation in cases when fMMC is diagnosed 
should not be directive. The decision of the prospective 
parents should be autonomous and based on the informa-
tion presented during the consultation. Informed consent 
should be obtained.
If the parents decide to choose IUMR or if the consulta-
tion about fMMC is problematic, all necessary help and quick 
pre-qualification is provided also via e-mail: spinabifida@
o2.pl, phone number: 32 7861540, or personal consultation at 
the Department of Gynecology, Obstetrics and Gynecologic 
Oncology in Bytom, Medical University of Silesia, Stefana 
Batorego 15, 41–902 Bytom, Poland. Patients with diagnosed 
fMMC should not be referred for pregnancy termination with-
out being fully informed about all possible treatment options.
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